Citations

Showing 10 of 107854 citations.

Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome
Quyyumi, Arshed A. , Prasad, Abhiram

Mayo Clinic

Circulation | September 13, 2004 | Volume: 110 | Issue: 11 | Pages: 1507-1512

10.1161/01.cir.0000141736.76561.78 | PMID 15364819 Get It

CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract
Brenchley, Jason M. , Schacker, Timothy W. , Ruff, Laura E., Price, David A. , Taylor, Jodie H., Beilman, Gregory J. , Nguyen, Phuong L., Khoruts, Alexander , Larson, Matthew , Haase, Ashley T. , Douek, Daniel C.

Mayo Clinic

The Journal of Experimental Medicine | September 13, 2004 | Volume: 200 | Issue: 6 | Pages: 749-759

10.1084/jem.20040874 | PMID 15365096 Get It

The mechanisms underlying CD4+ T cell depletion in human immunodeficiency virus (HIV) infection are not well understood. Comparative studies of lymphoid tissues, where the vast majority of T cells reside, and peripheral blood can potentially illuminate the pathogenesis of HIV-associated disease. Here, we studied the effect of HIV infection on the activation and depletion of defined subsets of CD4+ and CD8+ T cells in the blood, gastrointestinal (GI) tract, and lymph node (LN). We also measured HIV-specific T cell frequencies in LNs and blood, and LN collagen deposition to define architectural changes associated with chronic inflammation. The major findings to emerge are the following: the GI tract has the most substantial CD4+ T cell depletion at all stages of HIV disease; this depletion occurs preferentially within CCR5+ CD4+ T cells; HIV-associated immune activation results in abnormal accumulation of effector-type T cells within LNs; HIV-specific T cells in LNs do not account for all effector T cells; and T cell activation in LNs is associated with abnormal collagen deposition. Taken together, these findings define the nature and extent of CD4+ T cell depletion in lymphoid tissue and point to mechanisms of profound depletion of specific T cell subsets related to elimination of CCR5+ CD4+ T cell targets and disruption of T cell homeostasis that accompanies chronic immune activation.
REM Sleep Behavior Disorder in Parkinson’s Disease and Dementia with Lewy Bodies
Silber, Michael H. , Ferman, Tanis J. , Boeve, Bradley F. , Ferman, Tanis J

Mayo Clinic

Journal of Geriatric Psychiatry and Neurology | September 13, 2004 | Volume: 17 | Issue: 3 | Pages: 146-157

10.1177/0891988704267465 | PMID 15312278 Get It

Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia manifested by vivid, often frightening dreams associated with simple or complex motor behavior during REM sleep. Patients appear to “act out their dreams,” in which the exhibited behaviors mirror the content of the dreams. Management of RBD involves counseling about safety measures in the sleep environment; in those at risk for injury, clonazepam and/or melatonin is usually effective. In this article, the authors present a detailed review of the clinical and polysomnographic features, differential diagnosis, diagnostic criteria, management strategies, and pathophysiologic mechanisms of RBD. They then review the literature and their institutional experience of RBD associated with neurodegenerative disease, particularly Parkinson’s disease and dementia with Lewy bodies. The evolving data suggests that RBD may have clinical diagnostic and pathophysiologic significance in isolation and when associated with neurodegenerative disease. ( J Geriatr Psychiatry Neurol 2004; 17:146-157)
Noncoercive Sexual Contact with Similarly Aged Individuals
Friedrich, William N., Whiteside, Stephen P. H. , Talley, Nicholas J.

Mayo Clinic

Journal of Interpersonal Violence | September 13, 2004 | Volume: 19 | Issue: 9 | Pages: 1075-1084

10.1177/0886260504267583 | PMID 15296618 Get It

A community sample of 610 adults were grouped into those who reported no sexual abuse experience, others who reported noncoercive sexual contact with an individual that was at most 4 years older, and those who reported more severe sexual abuse. The first two groups did not differ from each other on current social support, trauma-specific symptomatology, and somatic complaints whereas the more severe sexual abuse group reported more problems on these dimensions. Further analyses suggested that of the two variables, coercion was more closely associated with problematic outcome than was the existence of an age difference.
Functional interaction between BLM helicase and 53BP1 in a Chk1-mediated pathway during S-phase arrest
Sengupta, Sagar , Robles, Ana I. , Linke, Steven P. , Sinogeeva, Natasha I., Pedeux, Rémy , Ward, Irene M., Celeste, Arkady, Nussenzweig, André , Halazonetis, Thanos D. , Harris, Curtis C. , Zhang, Ran , Chen, Junjie

Mayo Clinic

The Journal of Cell Biology | September 13, 2004 | Volume: 166 | Issue: 6 | Pages: 801-813

10.1083/jcb.200405128 | PMID 15364958 Get It

Bloom's syndrome is a rare autosomal recessive genetic disorder characterized by chromosomal aberrations, genetic instability, and cancer predisposition, all of which may be the result of abnormal signal transduction during DNA damage recognition. Here, we show that BLM is an intermediate responder to stalled DNA replication forks. BLM colocalized and physically interacted with the DNA damage response proteins 53BP1 and H2AX. Although BLM facilitated physical interaction between p53 and 53BP1, 53BP1 was required for efficient accumulation of both BLM and p53 at the sites of stalled replication. The accumulation of BLM/53BP1 foci and the physical interaction between them was independent of γ-H2AX. The active Chk1 kinase was essential for both the accurate focal colocalization of 53BP1 with BLM and the consequent stabilization of BLM. Once the ATR/Chk1- and 53BP1-mediated signal from replicational stress is received, BLM functions in multiple downstream repair processes, thereby fulfilling its role as a caretaker tumor suppressor.
Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis
Dispenzieri, Angela , Kyle, Robert A. , Lacy, Martha Q. , Burritt, Mary F., Therneau, Terry M. , Greipp, Philip R., Lust, John A., Rajkumar, S. Vincent , Fonseca, Rafaël , Zeldenrust, Steven R., McGregor, Christopher G.A. , Jaffe, Allan S. , Gertz, Morie A. , Witzig, Thomas E. , Jaffe, Allan S. , Rajkumar, S Vincent , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Journal of Clinical Oncology | September 13, 2004 | Volume: 22 | Issue: 18 | Pages: 3751-3757

10.1200/jco.2004.03.029 | PMID 15365071 Get It

Purpose Primary systemic amyloidosis (AL) is a multisystemic disorder resulting from an underlying plasma cell dyscrasia. There is no formal staging system for AL, making comparisons between studies and treatment centers difficult. Our group previously identified elevated serum cardiac troponin T (cTnT) as the most powerful predictor of overall survival. Others have reported that N-terminal pro-brain natriuretic peptide (NT-proBNP) is a valuable prognostic marker. We sought to develop a staging system for patients with AL. Patients and Methods Two hundred forty-two patients with newly diagnosed AL who were seen at the Mayo Clinic between April 1979 and November 2000, and who had echocardiograms and stored serum samples at presentation were eligible for this retrospective review. NT-proBNP measurements were performed on 242 patients in whom cTnT and cardiac troponin I (cTnI) had been previously run. Two prognostic models were designed using threshold values of NT-proBNP and either cTnT or cTnI (NT-proBNP < 332 ng/L, cTnT < 0.035 μg/L, and cTnI < 0.1 μg/L). Depending on whether NT-proBNP and troponin levels were both low, were high for only one level, or were both high, patients were classified as stage I, II, or III, respectively. Results Using the cTnT+NT-proBNP model 33%, 30%, and 37% of patients were stages I, II, and III, respectively, with median survivals of 26.4, 10.5, and 3.5 months, respectively. The alternate cTnI+NT-proBNP model predicted median survivals of 27.2, 11.1, and 4.1 months, respectively. Conclusion Stratification of AL patients into three stages is possible with two readily available and reproducible tests setting the stage for more consistent and reliable cross comparisons of therapeutic outcomes.
Epidemiologic Evaluation of Measurement Data in the Presence of Detection Limits
Lubin, Jay H. , Colt, Joanne S., Camann, David, Cerhan, James R. , Severson, Richard K., Hartge, Patricia, Davis, Scott , Bernstein, Leslie , Cerhan, James R

Mayo Clinic

Environmental Health Perspectives | September 13, 2004 | Volume: 112 | Issue: 17 | Pages: 1691-1696

10.1289/ehp.7199 | PMID 15579415 Get It

Abstract Quantitative measurements of environmental factors greatly improve the quality of epidemiologic studies but can pose challenges because of the presence of upper or lower detection limits or interfering compounds, which do not allow for precise measured values. We consider the regression of an environmental measurement (dependent variable) on several covariates (independent variables). Various strategies are commonly employed to impute values for interval-measured data, including assignment of one-half the detection limit to nondetected values or of “fill-in” values randomly selected from an appropriate distribution. On the basis of a limited simulation study, we found that the former approach can be biased unless the percentage of measurements below detection limits is small (5–10%). The fill-in approach generally produces unbiased parameter estimates but may produce biased variance estimates and thereby distort inference when 30% or more of the data are below detection limits. Truncated data methods (e.g., Tobit regression) and multiple imputation offer two unbiased approaches for analyzing measurement data with detection limits. If interest resides solely on regression parameters, then Tobit regression can be used. If individualized values for measurements below detection limits are needed for additional analysis, such as relative risk regression or graphical display, then multiple imputation produces unbiased estimates and nominal confidence intervals unless the proportion of missing data is extreme. We illustrate various approaches using measurements of pesticide residues in carpet dust in control subjects from a case–control study of non-Hodgkin lymphoma.
Angiogenesis and Anti-angiogenic Therapy in Myelofibrosis with Myeloid Metaplasia
Arora, Brijesh, Tefferi, Ayalew , Mesa, Ruben A.

Mayo Clinic

Leukemia & Lymphoma | September 10, 2004 | Volume: 45 | Issue: 12 | Pages: 2373-2386

10.1080/10428190400003267 | PMID 15621750 Get It

Clinically Translated Ischemic Stroke Genomics
Meschia, James F.

Mayo Clinic

Stroke | September 10, 2004 | Volume: 35 | Issue: 11_suppl_1 | Pages: 2735-2739

10.1161/01.str.0000143156.32467.fd | PMID 15359068 Get It

Cohort studies show that having a positive family history of stroke increases the odds of having a stroke by ≈30%. The heritability of stroke appears to be heterogeneous across ischemic stroke subtypes, with cardioembolic stroke being least heritable. The relative influence of stroke risk attenuates with age, but genetics does not cease to be relevant in later adulthood. Recent family history and twin studies suggest that genetic factors remain relevant even beyond the seventh decade of life. One of the challenges of gene discovery in stroke relates to the complexities of phenotype. The complexities of phenotype can be addressed by focusing on individual ischemic stroke subtypes or by studying intermediate phenotypes like leukaraiosis, which has a heritability of ≈70%. Although most stroke genetics research has focused on the identification of risk factor genes, an independent set of genes likely influences poststroke outcomes (for example, apolipoprotein E) and response to drug therapies (example, α-adducin and diuretic therapy).
Acquired α-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies
Steensma, David P. , Gibbons, Richard J. , Higgs, Douglas R. , Steensma, David P

Mayo Clinic

Blood | September 10, 2004 | Volume: 105 | Issue: 2 | Pages: 443-452

10.1182/blood-2004-07-2792 | PMID 15358626 Get It

AbstractAbnormalities of hemoglobin synthesis are usually inherited but may also arise as a secondary manifestation of another disease, most commonly hematologic neoplasia. Acquired hemoglobin disorders can be seen in any population and are not restricted to areas of the world with high incidences of inherited hemoglobinopathies. In fact, the acquired hemoglobinopathies may be more readily recognized where inherited hemoglobin abnormalities are rare and less likely to cause diagnostic confusion. Acquired α-thalassemia is the best characterized of the acquired red blood cell disorders in patients with hematologic malignancy, and it is almost always associated with a myelodysplastic syndrome (MDS). At least 2 molecular mechanisms for acquired α-thalassemia are now recognized: acquired deletion of the α-globin gene cluster limited to the neoplastic clone and, more commonly, inactivating somatic mutations of the trans-acting chromatin-associated factor ATRX, which cause dramatic down-regulation of α-globin gene expression. Here we review the clinical, hematologic, and molecular genetic features of α-thalassemia arising in a clonal myeloid disorder, and we discuss howATRX might affect gene expression in normal and abnormal hematopoiesis through epigenetic mechanisms.